Absolute Quantification of Prion Protein (90–231) Using Stable Isotope-Labeled Chymotryptic Peptide Standards in a LC-MRM AQUA Workflow
- 1.2k Downloads
Substantial evidence indicates that the disease-associated conformer of the prion protein (PrPTSE) constitutes the etiologic agent in prion diseases. These diseases affect multiple mammalian species. PrPTSE has the ability to convert the conformation of the normal prion protein (PrPC) into a β-sheet rich form resistant to proteinase K digestion. Common immunological techniques lack the sensitivity to detect PrPTSE at subfemtomole levels, whereas animal bioassays, cell culture, and in vitro conversion assays offer higher sensitivity but lack the high-throughput the immunological assays offer. Mass spectrometry is an attractive alternative to the above assays as it offers high-throughput, direct measurement of a protein’s signature peptide, often with subfemtomole sensitivities. Although a liquid chromatography-multiple reaction monitoring (LC-MRM) method has been reported for PrPTSE, the chemical composition and lack of amino acid sequence conservation of the signature peptide may compromise its accuracy and make it difficult to apply to multiple species. Here, we demonstrate that an alternative protease (chymotrypsin) can produce signature peptides suitable for a LC-MRM absolute quantification (AQUA) experiment. The new method offers several advantages, including: (1) a chymotryptic signature peptide lacking chemically active residues (Cys, Met) that can confound assay accuracy; (2) low attomole limits of detection and quantitation (LOD and LOQ); and (3) a signature peptide retaining the same amino acid sequence across most mammals naturally susceptible to prion infection as well as important laboratory models. To the authors’ knowledge, this is the first report on the use of a non-tryptic peptide in a LC-MRM AQUA workflow.
Key wordsProtein quantification Multiple reaction monitoring (MRM) AQUA Prion Stable isotope labeled reference for absolute quantitation Chymotrypsin
Transmissible spongiform encephalopathies (TSEs) or prion diseases are a family of fatal neurodegenerative diseases that affect humans (Creutzfeldt-Jakob disease, CJD) and a variety of farmed and free-ranging mammals, including cattle (bovine spongiform encephalopathy, BSE), sheep and goats (scrapie), North American members of the deer family (chronic wasting disease, CWD), and mink (transmissible mink encephalopathy, TME) [1, 2, 3, 4, 5, 6]. Prion diseases are unique among protein misfolding disorders in that they are transmissible. Sheep scrapie and CWD appear unique among prion diseases in that epizootics can be sustained through horizontal transmission and that an environmental reservoir of infectivity can contribute to transmission [4, 7, 8, 9, 10, 11, 12, 13, 14, 15]. Chronic wasting disease in captive and free-ranging animals and BSE in domestic cattle have caused substantial agricultural, economic, and social impacts. Bovine spongiform encephalopathy has transmitted to humans in the form of variant CJD, raising concern about the potential for CWD to cross the human species barrier [16, 17, 18, 19, 20]. The pathogenic prion protein, denoted as PrPTSE, can induce conformational changes in the normal, benign cellular form of the protein, PrPC, leading to disease propagation and accumulation of PrPTSE . The cellular and pathogenic isoforms of the prion protein possess identical primary sequences and covalent post-translational modifications, and differ only in their conformation [21, 22, 23, 24, 25, 26, 27]. Circular dichroism and infrared spectroscopy studies have indicated that conversion of PrPC to PrPTSE is accompanied by a dramatic increase β-sheet content [28, 29]. The differences in secondary and higher order structures of PrPC and PrPTSE confer on them profoundly different biophysical properties. PrPC is susceptible to proteolysis, is soluble in water and detergents, and exists as a monomer. In contrast, PrPTSE is partially resistant to proteolysis, insoluble in water and non-denaturing detergents, and has a propensity to aggregate. Differences in protease resistance is frequently used to discriminate between the two conformers. Treatment of PrPTSE with proteinase K (PK) yields the PK-resistant core of the molecule, denoted PrP27-30 because of the position to which it migrates in SDS-PAGE. In contrast, similar treatment of PrPC leads to the generation of many small peptide fragments . Therefore, PK-treatment of PrPC or PrPTSE yields distinct peptide products, enabling their detection and quantification.
Detection and quantification of PrPTSE remain challenging. An intracerebral infectious dose of PrPTSE for hamsters has been estimated to contain ~104 to 105 molecules (~0.02 to 0.2 amol) [30, 31]. The most widely employed methods to detect prions and PrPTSE are animal bioassay and immunological assays. Animal bioassay is the most direct technique to measure prion infectivity and is considered the “gold standard” for prion detection, but is animal-intensive, time-consuming, expensive, and generally limited to rodent-adapted prion strains, or requires the use of transgenic mice expressing the prion protein of interest . Immunologic assays such as Western blotting, enzyme-linked immunosorbent assays, and a conformation-dependent immunoassay are commonly used in prion research but have limits of detection (LOD) from 20 to 0.1 pmol [33, 34, 35, 36, 37, 38, 39, 40]. Other classes of prion detection methods are in vitro conversion assays and cell culture methods. Protein misfolding cyclic amplification (PMCA) is a powerful prion conversion assay that exploits the ability of PrPTSE to convert PrPC to a PK-resistant form in a manner conceptually similar to the polymerase chain reaction [41, 42, 43]. Many amplification/conversion cycles can be performed to increase PrPTSE levels 10- to 107-fold prior to detection . A drawback of this method is that amplification of PrPTSE can take several days to achieve ultrasensitivity, stringent conditions are required to prevent false positive results , and levels of PrPTSE are not directly measured. Addition of polymeric beads to PMCA reactions has recently been shown to improve the robustness of the method [45, 46]. Cell culture-based methods have recently been reported for several economically important species [47, 48].
Mass spectrometry-based methods using stable isotope-labeled standards (SIS) for absolute quantification (AQUA) represent an attractive alternative to the prion detection methods mentioned above. The AQUA method involves introducing a known concentration of a SIS peptide to a protein digest that yielded the same unlabeled peptide. Peptide abundances of the two peptides (SIS and native) are then measured by liquid-chromatography with multiple reaction monitoring (LC-MRM), and the concentration of the targeted protein is calculated using a calibration curve. This method allows sub-femtomole quantification of proteins in complex mixtures [49, 50].
A LC-MRM assay was recently reported for the detection and quantitation of PrPTSE in Syrian hamster brain homogenate [51, 52]. A potential drawback to the reported method is that the signature tryptic peptide used for quantitation contains two chemically reactive residues (Cys, Met) that could compromise assay accuracy. Furthermore, although a high degree of sequence identity exists across mammalian species, the primary structure differs slightly in each . This would require that the tryptic SIS peptide to be revalidated for additional species , adding expense to the lab.
Our work explores the use of alternative proteases to produce a peptide suitable for LC-MRM AQUA assays of prion protein. A suitable AQUA peptide is defined here as (1) lacking chemically active residues (Cys, Met) that can compromise the accuracy of the assay, (2) providing sub-femtomole LOD and LOQ, and (3) identical across multiple mammalian species susceptible to natural prion disease or used as laboratory models. Many LC-MRM AQUA publications mention in passing that proteases other than trypsin could, in principle, be used to produce a peptide suitable for a quantification assay [50, 55], but to the authors’ knowledge, accounts of other enzymes being utilized for this type of assay have not been published. Thus, our work reports the first application of a non-tryptic peptide in a LC-MRM AQUA workflow.
Iodoacetamide (IAA), β-octyl glucopyranoside (BOG), α-cyano-4-hydroxycinnamic acid (CHCA), thermolysin, trifluoroacetic acid (TFA), and hydrofluoric acid (HF) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Ammonium bicarbonate, formic acid (FA), and heavy AQUA peptides RPV[13C5,15N]DQY, YRPV[13C5,15N]DQY, and FL[13C6,15N2]NPWEK were supplied by Thermo Fisher Scientific (Waltham, MA, USA). Dithiothreitol (DTT) and sequence-grade modified trypsin were purchased from Promega (Madison, WI, USA). Bovine chymotrypsin and glutamic acid-C (Glu-C) were purchased from Princeton Separations (Adelphia, NJ, USA). Bovine recombinant prion protein (bovine rPrP) was purchased from Abcam (Cambridge, MA, USA). Syrian hamster recombinant prion protein (hamster rPrP90-231) was supplied by Jena Bioscience (Jena, Germany). Sterile filtered mouse serum was purchased from Equitech-Bio, Inc. (Kerrville, TX, USA). The 18 MΩ∙cm water used in these experiments was obtained from a Milli-Q purification system (Millipore, Bedford, MA, USA). The LC-MS grade solvents acetonitrile (ACN) and water for the Waters nanoAcquity UPLC (Milford, MA, USA) were purchased from Burdick and Jackson (Muskegon, MI, USA). The Optima grade solvents ACN and water for the Eksigent Ultra 2D UPLC (Dublin, CA, USA) were purchased from Fisher Scientific (Fair Lawn, NJ, USA).
2.2 Chymotrypsin, Trypsin, Glu-C, and Thermolysin Digestions for AQUA Peptide Identification
Bovine rPrP (5 μL, 1 μg∙μL–1) was combined with 15 μL 0.01 % BOG (wt/vol) and sonicated for 5 min in an ultrasonic bath. Cysteine residues in bovine rPrP were reduced with 10 μL 10 mM DTT prepared in buffer A (25 mM ammonium bicarbonate in 0.01 % BOG [wt/vol]) for 1 h at 37 °C. After cooling to room temperature, cysteines were alkylated with 40 μL 10 mM IAA in darkness for 1 h at room temperature. Alkylation was quenched by incubation in 20 μL 10 mM DTT for 15 min at room temperature. All digestions were performed under the manufacturer’s suggested conditions: chymotrypsin (1:50 enzyme:protein ratio, 30 °C, 9 h); Glu-C (1:20 enzyme:protein ratio, 25 °C, 16 h); thermolysin (1:25 enzyme:protein ratio, 37 °C, 24 h); and trypsin (1:50 ratio, 37 °C, 16 h). Each digest was quenched by addition of 2.5 μL 10 % (vol/vol) FA(aq), desalted with C18 OMIX pipette tip (Agilent Technologies, Santa Clara, CA, USA), and concentrated by speedvac (Thermo Scientific, Waltham, MA, USA). Dried eluent was resuspended in 60 μL 50 % ACN/0.1 % TFA(aq) (vol/vol) and stored at 4 °C until analysis on a Bruker amaZon ETD ion trap (Billerica, MA, USA) mass spectrometer.
2.3 Optimization of Chymotrypsin Digestion Time
Three 5 μL aliquots of hamster rPrP90-231 (1 μg∙μL–1) were reduced, alkylated, and chymotrypsinized as described above except the total volume was diluted to 100 μL. At desired time points, 20 μL aliquots of each digest were removed, and 0.5 μL (0.1 μg∙μL–1) fresh chymotrypsin was added to each digestion tube. The chymotryptic digestion in each aliquot was quenched by addition of 1 μL 10 % FA(aq) (vol/vol), and the reaction was desalted with C18 OMIX pipette tip and concentrated by speedvac. Concentrated samples were reconstituted in 100 μL 3%ACN/FA(aq) (vol/vol) containing SIS peptide YRPVDQY. Subsequent serial dilutions yielded final analyte and internal standard concentrations of 5 fmol∙μL–1 and 10 fmol∙μL–1, respectively. Each time-point sample was analyzed in triplicate using a Bruker Autoflex III TOF/TOF and AB SCIEX 5500 QTRAP (Foster City, CA, USA) mass spectrometer.
2.4 Hamster rPrP90-231 Quantification
Three 2 μL aliquots of hamster rPrP90-231 (1 μg∙μL–1) were reduced, alkylated and chymotrypsinized (vide supra). Chymotryptic digestion was allowed to proceed for 9.5 h before 2.5 μL 10 % FA(aq) (vol/vol) was added to quench the reaction. A 5 μL aliquot of the digest was placed in 45 μL 0.1 % FA(aq) (vol/vol) containing 11.1 fmol∙μL–1 SIS peptides RPVDQY and YRPVDQY, desalted with C18 OMIX pipette tip, and concentrated by speedvac. Concentrated samples were reconstituted in 200 μL 3 % FA(aq) (vol/vol). Each digest was analyzed in triplicate on an AB SCIEX 5500 QTRAP mass spectrometer.
2.5 Qualitative Mass Spectrometry
Bovine rPrP peptide fragments produced by tryptic, chymotryptic, thermolytic, and Glu-C digestions were identified by nanoESI-direct infusion (300 nL∙min–1) into a Bruker amaZon ETD ion trap mass spectrometer. In addition, digestions were analyzed by nanoLC-MS/MS using an Eksigent Ultra 2D UPLC. Mobile phase A was water in 0.1 % FA(aq) (vol/vol), and mobile phase B was ACN. Samples were introduced into the system by a 5 μL injection onto an Agilent Technologies Zorbax 300 SB-C18 5 μm, 5 × 0.3 mm trap cartridge (Santa Clara, CA, USA) at a flow rate of 5 μL∙min–1 of 95 % mobile phase A for 5 min. Peptides were separated on a 3 μm Waters Atlantis dC18 75 μm × 150 mm column (Milford, MA, USA) with a 40 min gradient from 5 % to 35 % mobile phase B at a flow rate of 250 nL∙min–1 and column temperature of 30 °C. Electrospray emitter tips were prepared in house from 75 μm i.d., 360 μm o.d. capillary tubing (Polymicro Technologies, Phoenix, AZ, USA) using a Sutter P-2000 laser capillary puller (Novato, CA, USA).
Capillary voltage was set to −1300 V, end plate offset voltage was −500 V, dry gas flow was 4.0 L∙min–1, and dry gas temperature was 125 °C. MS data were acquired from 300 to 1700 m/z in enhanced resolution mode (8100 m/z s–1) with a target mass of 700 m/z and trap drive level of 100 %. CAD MS2 spectra were manually collected with a 1-V MS/MS fragmentation amplitude, and smart fragmentation was set at 30 % to 300 %.
Bovine rPrP peptide fragments produced by chymotryptic digestion in the timed digestion experiment were identified using a Bruker autoflex III MALDI TOF/TOF mass spectrometer. For this analysis, equal volumes (0.5 μL) of reconstituted digest and matrix solution, consisting of 5 mg CHCA dissolved in 1 mL 50 % ACN/0.1 % TFA(aq) (vol/vol), were mixed on a ground-steel plate and allowed to dry. Mass spectra were acquired in reflectron positive ion mode with a 200 Hz repetition rate averaging 500 laser shots.
In silico tryptic, chymotryptic, thermolytic, and Glu-C digestions of bovine and hamster rPrP were performed using MS-Digest tool from the Protein Prospector suite (http://prospector.ucsf.edu, v. 5.9.2) developed by UCSF. Carbamidomethylation was set as a static modification, methionine oxidation was selected as a variable modification, the minimum peptide length equaled five, peptide mass ranged from 300 to 2500 m/z, and multiple charged ions were reported in the algorithm’s output. Prion protein amino acid alignment was carried out with Jalview software (http://www.jalview.org/download.html) [56, 57] and the clustalW alignment algorithm . Protein sequences were from uniprot/swissprot knowledgebase (http://www.uniprot.org/help/uniprotkb).
2.6 Quantitative Mass Spectrometry
LC-MRM experiments were performed with a Waters nanoAcquity UPLC connected online with an AB SCIEX 5500 QTRAP equipped with a nanospray III ion source. Initial experiments to manually optimize instrument response for YRPVDQY and FLNPWEK were done by direct infusion. The two peptides (2.5 pmol∙μL–1 in 50 % ACN/ 0.1 % FA(aq) [vol/vol]) were infused into the mass spectrometer at 500 nL∙min–1. A precursor scan was used to confirm the presence of analyte ions in the mass spectrometer, and a product ion scan was used to determine the dominant MS2 fragment peaks. Curtain gas, ionspray voltage, ion source gas 1, interface heater temperature, and ESI emitter position were optimized for the precursor signal, while the declustering potential (DP), entrance potential (EP), collision energy (CE), and collision cell exit potential were optimized for each precursor/product ion MRM transition to obtain maximum analyte/MRM intensity while maintaining stable electrospray intensity. Instrument settings for RPVDQY were optimized using Skyline software (https://skyline.gs.washington.edu, v. 0.7) developed by the MacCoss Lab .
For LC-MRM experiments curtain gas was set to 20 psi, collision gas was medium, ionspray voltage was 2300 V, ion source gas 1 was set to 16 psi, and interface heater temperature was 150 °C. UPLC elution solvents were: A (0.1 % FA(aq) [vol/vol]) and B (ACN/0.1 % FA(aq) [vol/vol]). Samples resuspended in 3 % ACN/ 0.1 % FA(aq) (vol/vol) were loaded onto a self-packed C18 trap cartridge (Phenomenex Jupiter C18 5 μm, 100 μm × 70 mm; ) at a flow rate of 2.00 μL∙min–1 solvent A over 10.0 min. Samples were eluted from a self-packed reversed-phase column (Phenomenex Jupiter C18 5 μm, 75 μm × 120 mm) integrated with a HF etched 8 μm ESI emitter tip (Sutter Instrument P-2000, Novato, CA, USA) using an 11 min linear gradient from 3 % to 35 % solvent B at a flow rate of 500 nL∙min–1. Solvent B was raised to 70 % to elute remaining peptides, and the column was re-equilibrated for 10 min in 3 % solvent B prior to injection of the next sample. The mass spectrometer was operated in MRM mode, alternating between detection of YRPVDQY (ion transitions m/z 470.7+2 to 759.3+1 [b6], 470.7+2 to 631.3+1 [b5], 470.7+2 to 182.1+1 [y1]), and YRPV[13C5,15N]DQY (ion transitions m/z 473.7+2 to 765.3+1 [b6], 473.7+2 to 637.3+1 [b5], 473.7+2 to 182.1+1 [y1]), RPVDQY (ion transitions m/z 389.2+2 to 596.3+1 [b5], 389.2+2 to 468.3+1 [b4], 389.2+2 to 182.1+1 [y1]), RPV[13C5,15N]DQY (ion transitions m/z 392.2+2 to 602.3+1 [b5], 392.2+2 to 474.3+1 [b4], 392.2+2 to 182.1+1 [y1]). Q1 and Q3 were operated in unit resolution mode, and dwell time for each transition was set to 40 ms. Quantification was performed with the IntelliQuan quantification algorithm of Analyst 1.5.1 software (AB SCIEX) using default parameters. Calibration curves, proteolysis time, and digest accuracy graphs were prepared using Graphpad Prism (v. 5.0) software.
3 Results and Discussion
3.1 Identifying a Non-Tryptic Peptide for AQUA Quantification of PrPTSE
We simulated digestion of the proteinase K-resistant core of Syrian hamster and bovine PrPTSE by 13 proteases in silico with Protein Prospector’s MS-Digest algorithm: trypsin, chymotrypsin, Lys C, Lys N, pepsin, Arg C, Asp N, Asp C, DE-N, Glu-C, Tyr-C, thermolysin, and Pro-C. Chymotrypsin, Glu-C, and thermolysin showed promise in that they produced peptides in silico that met our first criterion for a suitable AQUA peptide (Supplemental Table 1): lack of chemically active residues (Cys, Met) that can compromise assay accuracy (Supplemental Figure 1). Chymotrypsin cleaves peptide bonds predominantly on the carboxyl side of Tyr, Phe, and Trp. Glu-C cleaves peptide bonds at the carboxyl side of Glu residues. Thermolysin is predicted to cleave peptides at the N-terminal side of hydrophobic amino acid residues Leu, Ile, Phe, Val, Ala, and Met .
After identifying proteases that may potentially produce a peptide meeting our first criterion, trypsin, chymotrypsin, Glu-C, and thermolysin digestions were performed according to manufacturers’ instructions. Desalted proteolytic digests were directly infused into a Bruker amaZon ETD ion trap mass spectrometer and also subjected to nanoLC-MS/MS analysis to experimentally determine which peptides predicted in in silico digests warranted further consideration for a quantitative assay.
Trypsin was included in the initial screening of proteases because it had previously been used for prion quantification [51, 52, 54, 61]. Supplemental Figure 1 demonstrates that bovine rPrP tryptic peptide VVEQMCITQYQR was observed in both its normal (a) and sulfoxide forms (b) during nanoLC-MS/MS analysis. Supplemental Figure 1c shows that the SIS peptide VVEQMCTTQYQK was also observed in its normal and sulfoxide forms during nanoLC-MS/MS analysis. Recently, researchers have started monitoring both normal and sulfoxide forms of the native and SIS tryptic AQUA peptides for quantification assays [54, 62], but as Supplemental Figure 1c shows, the possibility still exists for the normal SIS peptide to contribute to the sulfoxide SIS peak, and for the sulfoxide SIS peptide to further oxidize to the sulfone state, thereby confounding quantification [63, 64, 65]. This observation drove us to identify and use a peptide lacking chemically reactive residues to use as a signature peptide for LC-MRM quantification of prion protein.
Target peptides from the Glu-C and thermolysin digests were not observed at high intensities in either the direct infusion or online nanoLC analyses (data not shown). In contrast, chymotrypsin generated an intense ion peak at m/z 470.7 (2+) corresponding to the doubly charged peptide ion YRPVDQY. We originally targeted RPVDQY as a potential peptide for MRM quantification, but we did not observe ions for this peptide during direct infusion or nanoLC-MS/MS analyses (Supplemental Figure 2). Instead, the predominant ion observed was the doubly charged YRPVDQY ion (one missed cleavage). The reason that production of the missed cleavage form of RPVDQY dominates over that of the fully digested form is unclear. However, the doubly charged YRPVDQY peptide ion met our first criterion for a suitable AQUA peptide since it lacks chemically reactive Cys and Met residues. We assessed the peptide’s specificity to prion protein by performing an NCBI BLAST search against non-redundant protein sequences. Results indicated that YRPVDQY is unique to prion protein. We therefore further investigated this peptide.
We also investigated whether known species-specific polymorphisms in prion protein could affect this LC-MRM assay. The sequence YRPVDQY is conserved across the cervid, bovid, and rodent species presented in Figure 1. For a polymorphism to affect this assay, the amino acid substitution would have to occur within residues 163 to 169. Substitution of amino acid 169 with a residue other than Phe or Trp would prevent production of the chymotryptic AQUA peptide and would interfere with analysis. Cervids have at least 20 known polymorphisms, but only seven of these alter the primary sequence of PrP [5, 67], and none affect amino acids 163 to 169 or the generation of the chymotryptic peptide. Thirteen polymorphisms have been identified in the bovine Prnp gene with only three affecting the translated protein and none impacting this assay [67, 68]. In the case of rodents, Syrian hamsters have no known polymorphisms and mice only have two polymorphisms (L108F and T189V), neither of which would interfere with the assay developed here . Although voles have several known polymorphisms, none of them occur between residues 163 and 169 . Therefore, the likelihood that polymorphisms in Prnp gene for these species to hinder the efficacy of the LC-MRM method presented here is considered low, making this method generally applicable for a wide range of species.
3.2 Determining the Limits of Quantification (LOQ) and Detection (LOD) for YRPVDQY
Optimized MRM Transitions for Selected Chymotryptic Peptides Derived from Bovine and Hamster rPrPs a
Precursor ion (m/z; z = +2)
Declustering potential (volts)
Collision energy (volts)
Product ion (m/z; z = +1)
3.3 Optimization of Chymotrypsin Digestion Time
Calibration Curve Statistics for YRPVDQY and RPVDQY MRM Quantification Transitions a
Expected amount (fmol)
# of replicates
Calculated amount (fmol)
YRPV*DQY, b6 transition
RPV*DQY, b5 transition
3.4 Hamster rPrP90-231 Quantification by LC-MRM
We tested the performance of our LC-MRM AQUA method on a chymotryptic digest of known amount of an N-terminally truncated form of Syrian hamster rPrP (rPrP90-231). We used rPrP90-231 rather than intact rPrP because in biological samples PK digestion is used to discriminate PrPC from PrPTSE. Upon proteolysis, PrPC is broken up into small peptide fragments, whereas a core of PrPTSE (amino acids 90–231) remains intact . After PK digestion, PrPTSE would be denatured with 6 M guanidine hydrochloride and then precipitated with methanol to prepare the truncated protein for chymotryptic digestion. Here, three 2-μg aliquots of hamster rPrP90-231 were digested with chymotrypsin. Sample preparation was comprised of reduction/alkylation, digestion, addition of SIS peptides, OMIX C18 pipette tip desalting, speedvac concentration, and sample re-suspension/dilution. Recovery experiments were performed to estimate the overall yield of YRPVDQY and RPVDQY after the sample preparation steps. Chymotryptic digests of PrP90-231 ranging from 1 to 100 fmol∙μL–1 rPrP90-231 were found to have recoveries of 60 % to 81 %, respectively. The 2 μg digests were diluted so that for a 2.0 μL injection the amounts of native RPVDQY and YRPVDQY would sum to approximately 62.7 fmol on-column when measured. SIS peptides for YRPVDQY and RPVDQY were spiked into the digests so the total injected amount of each SIS would be 10 fmol on-column.
Mass spectrometry represents an attractive alternative to more commonly used assays to measure prions because it offers high-throughput, direct measurement of a protein’s signature peptide with subfemtomole sensitivities. Using recombinant forms of the prion protein we demonstrated the utility of a signature peptide produced via chymotrypsin digestion for a LC-MRM AQUA assay. Our new peptides meet the following criteria: (1) lack of chemically active residues (Cys, Met) that can confound assay accuracy, (2) provision of subfemtomole LOD and LOQ, and (3) identical amino acid sequences across multiple commercially and experimentally important mammalian species. Chymotryptic peptides YRPVDQY and RPVDQY do not contain residues susceptible to modification during sample handling and analysis that could hinder quantification experiments. Each provides low attomole LOD and LOQ sensitivities while maintaining a dynamic range over 3.5 orders of magnitude. In addition, both peptides show a high degree of conservation across mammalian species and should not be affected by known polymorphisms. When used to quantify recombinant prion protein, quantification accuracy error was minimal (<3 %). The LC-MRM approach presented here is expected to translate well into research studying pathogenic prion protein in a large number of mammalian species. We are currently applying this assay to a variety of mammalian species. In summary, we present an inexpensive, high-throughput, and accurate LC-MRM AQUA method for quantification of prion protein in a variety of economically and research important species. To the authors’ knowledge, this is the first report of an LC-MRM AQUA method utilizing signature peptides derived from a non-tryptic peptide.
The authors thank the Analytical Instrumentation Center at the University of Wisconsin-Madison School of Pharmacy for the access to the amaZon ETD ion trap, and Bruker Daltonics for graciously loaning the autoflex III MALDI TOF/TOF mass spectrometer. R.S. acknowledges the NIH-supported Clinical Neuroengineering Training Program Predoctoral Fellowship (NRSA T32 EB011434). G.S. was supported by an NHGRI training grant to the Genomic Sciences Training Program (5T32HG002760). L.M.S. acknowledges support from the Wisconsin Center of Excellence in Genomics Science through NIH/NHGRI grant 1P50HG004952. L.L. acknowledges support from the Wisconsin Alumni Research Foundation and an H. I. Romnes Faculty Research Fellowship. This work was supported by NSF CAREER grant CBET-0547484 (J.A.P.).
- 2.Baeten, L.A., Powers, B.E., Jewell, J.E., Spraker, T.R., Miller, M.W.: A natural case of chronic wasting disease in a free-ranging moose (Alces alces shirasi). J. Wildl. Dis. 43, 309 (2007)Google Scholar
- 4.Mathiason, C.K., Hays, S.A., Powers, J., Hayes-Klug, J., Langenberg, J., Dahmes, S.J., Osborn, D.A., Miller, K.V., Warren, R.J., Mason, G.L., Hoover, E.A.: Infectious prions in preclinical deer and transmission of chronic wasting disease solely by environmental exposure. PLoS One 4, e5916 (2009)CrossRefGoogle Scholar
- 6.Williams, E.S., Young, S.: Chronic wasting disease of captive mule deer: A spongiform encephalopathy. J. Wildl. Dis. 16, 89–98 (1980)Google Scholar
- 7.Miller, M., Wild, M., Williams, E.: Epidemiology of chronic wasting disease in captive rocky mountain elk. J. Wildl. Dis. 34, 532 (1998)Google Scholar
- 8.Miller, M., Williams, E., McCarty, C., Spraker, T., Kreeger, T., Larsen, C., Thorne, E.: Epizootiology of chronic wasting disease in free-ranging cervids in Colorado and Wyoming. J. Wildl. Dis. 36, 676–690 (2000)Google Scholar
- 10.Williams, E., Miller, M.: Chronic wasting disease in deer and elk in North America. Rev. Sci. Tech. 21, 305–316 (2002)Google Scholar
- 14.Pálsson, P.: Rida (Scrapie) in Iceland and its epidemiology. In: Prusiner, S.B., Hadlow, W.J. (eds.) Slow Transmissible Diseases of the Nervous System, pp. 357–366. Academic Press, New York (1979)Google Scholar
- 16.Michigan Surveillance and Response Plan for Chronic Wasting Disease of Free-Ranging and Privately-Ownned/Captive Cervids. 1–19 (2002)Google Scholar
- 17.Wisconsin’s Chronic Wasting Disease Response Plan: 2010–2025. 1–44 (2010)Google Scholar
- 19.Joly, D.O., Samuel, M.D., Langenberg, J.A., Blanchong, J.A., Batha, C.A., Rolley, R.E., Keane, D.P., Ribic, C.A.: Spatial epidemiology of chronic wasting disease in Wisconsin white-tailed deer. J. Wildl. Dis. 42, 578–588 (2006)Google Scholar
- 22.Baldwin, M.A., Stahl, N., Reinders, L.G., Gibson, B.W., Prusiner, S.B., Burlingame, A.L.: Permethylation and tandem mass spectrometry of oligosaccharides having free hexosamine: Analysis of the glycoinositol phospholipid anchor glycan from the scrapie prion protein. Anal. Biochem. 191, 174–182 (1990)CrossRefGoogle Scholar
- 29.Safar, J., Roller, P.P., Gajdusek, D.C., Gibbs, C.J.: Conformational transitions, dissociation, and unfolding of scrapie amyloid (prion) protein. J. Biol. Chem. 268, 20276–20284 (1993)Google Scholar
- 33.Biffiger, K., Zwald, D., Kaufmann, L., Briner, A., Nayki, I., Pürro, M., Bottcher, S., Struckmeyer, T., Schaller, O., Meyer, R., Fatzer, R., Zurbriggen, A., Stack, M., Moser, M., Oesch, B., Kübler, E.: Validation of a luminescence immunoassay for the detection of PrPSc in brain homogenate. J. Virol. Methods 101, 79–84 (2002)CrossRefGoogle Scholar
- 36.Lee, D.C., Stenland, C.J., Hartwell, R.C., Ford, E.K., Cai, K., Miller, J.L., Gilligan, K.J., Rubenstein, R., Fournel, M., Petteway, S.R.: Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein. J. Virol. Methods 84, 77–89 (2000)CrossRefGoogle Scholar
- 39.Zanusso, G., Righetti, P.G., Ferrari, S., Terrin, L., Farinazzo, A., Cardone, F., Pocchiari, M., Rizzuto, N., Monaco, S.: Two-dimensional mapping of three phenotype-associated isoforms of the prion protein in sporadic creutzfeldt-jakob disease. Electrophoresis 23, 347–355 (2002)CrossRefGoogle Scholar
- 40.Safar, J.G., Scott, M., Monaghan, J., Deering, C., Didorenko, S., Vergara, J., Ball, H., Legname, G., Leclerc, E., Solforosi, L., Serban, H., Groth, D., Burton, D.R., Prusiner, S.B., Williamson, R.A.: Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice. Nat. Biotechnol. 20, 1147–1150 (2002)CrossRefGoogle Scholar
- 41.Castilla, J., Saa, P., Soto, C.: Detection of prions in blood. Nat. Med. 11, 982–985 (2005)Google Scholar
- 46.Johnson, C.J., Aiken, J.M., McKenzie, D., Samuel, M.D., Pedersen, J.A.: Highly efficient amplification of chronic wasting disease agent by protein misfolding cyclic amplificatoin with beats (PMCAb). PLoS ONE e35383 (2012)Google Scholar
- 66.Prusiner, S.B., Safar, J., DeArmond, S.J.: Bioassays of prions. In: Prusiner, S.B. (ed.) Prion Biology and Diseases. Cold Spring Harbor Laboratory Press: pp 143–186 (2003)Google Scholar
- 70.Agrimi, U., Nonno, R., Dell’Omo, G., Di Bari, M.A., Conte, M., Chiappini, B., Esposito, E., Di Guardo, G., Windl, O., Vaccari, G., Lipp, H.P.: Prion protein amino acid determinants of differential susceptibility and molecular feature of prion strains in mice and voles. PLoS Pathog. 4, e1000113 (2008)CrossRefGoogle Scholar
- 72.Blow, D.M.: The structure of chymotrypsin. In: Boyer, P.D. (ed.) The Enzymes, pp. 185–212. Academic Press, New York (1971)Google Scholar
- 73.Hess, G.P.: Chymotrypsin-chemical properties and catalysis. In: Boyer, P.D. (ed.) The Enzymes, pp. 213–248. Academic Press, New York (1971)Google Scholar
- 75.USFDA: Guidance for industry: Bioanalytical method validation. (2001)Google Scholar